Chinese Biotechs Shift From Building to Partnering as Deal Values Double
At BIO China, pharma executives and investors debated whether Chinese biotechs should pursue full integration or adopt partnership-led growth...
licensing deals
China Biotech Dealmaking Shifts from Opportunistic to Strategic
At BIO-Europe Spring 2026, industry leaders from AstraZeneca, Kelun-Biotech, Harbour BioMed, and Panacea Capital dissected the structural forces driving...